The natural history of PBC: Has it changed?

Seminars in Liver Disease

Volumn 25, Issue 3, 2005, Pages 321-326

  Lee, Young Mee ^a   Kaplan, Marshall M ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

Natural history; Outcomes; Primary biliary cirrhosis; Prognosis; Survival

Indexed keywords

COLCHICINE; METHOTREXATE; URSODEOXYCHOLIC ACID;

DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; SYMPTOMATOLOGY;

CHOLAGOGUES AND CHOLERETICS; ESOPHAGEAL AND GASTRIC VARICES; HUMANS; LIVER CIRRHOSIS, BILIARY; MODELS, THEORETICAL; PROGNOSIS; SURVIVAL; URSODEOXYCHOLIC ACID;

EID: 24344499744     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916323     Document Type: Review

References (32)

1. Prince MI, James OF. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003;7:795-819
2. MacMahon HE, Tannhauser SJ. Xanthomatous biliary cirrhosis (a clinical syndrome). Ann Intern Med 1949;30: 121-131
3. Ahrens EJ, Payne M, Kunkel H, et al. Primary biliary cirrhosis. Medicine 1950;29:299-364
4. Sherlock S. Primary biliary cirrhosis (chronic intrahepatic cholestasis). Gastroenterology 1959;31:574-582
5. Long RG, Scheurer PJ, Sherlock S. Presentation and course of asymptomatic primary biliary cirrhosis. Gastroenterology 1977;72:1204-1207
6. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983;308:1-7
7. Balasubramaiam K, Grambsch PM, Wiesner RH, et al. Diminished survival in asymptomatic primary biliary cirrhosis: a prospective study. Gastroenterology 1990;98:1567-1571
8. Mahl TC, Shockcor W, Boyer JL. Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J Hepatol 1994;20:707-713
9. Pares A, Rodes J. Natural history of primary biliary cirrhosis. Clin Liver Dis 2003;7:779-794
10. Springer J, Cauch-Dudek K, O'Rourke K, Wanless I, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999;94:47-53
11. Prince MI, Chetwynd A, Craig WL, et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004;53:860-870
12. Christensen E, Neuberger J, Crowe J, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis: final result of an international trial. Gastroenterology 1985;89:1084-1091
13. Locke GR, Therneau TM, Ludwig J, Dickson ER, Lindor KD. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996;23:52-56
14. Angulo P, Batts KP, Therneau TM, et al. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999;29:644-647
15. Degott C, Zafrani ES, Callard P, et al. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999;29:1007-1012
16. Pares A, Caballeria L, Rodes J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. J Hepatol 2000;32: 561-566
17. Corpechot C, Carrat F, Bonnand A. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primay biliary cirrhosis. Hepatology 2000;32:1196-1199
18. Poupon RE, Lindor KD, Pares A, et al. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003;39: 12-16
19. Gores GJ, Wiesner RH, Dickson ER, et al. Prospective evaluation of esophageal varices in primary biliary cirrhosis: development, natural history, and influence on survival. Gastroenterology 1989;96:1552-1559
20. Takeshita E, Kumagi T, Matsui H, et al. Esophagogastric varices as a prognostic factor for the determination of clinical stage in patients with primary biliary cirrhosis. J Gastroenterol 2003;38:1060-1065
21. Lindor KD, Jorgensen RA, Therneau TM, et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc 1997;72:1137-1140
22. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989;10: 846-850
23. Poupon RE, Lindor KD, Cauch-Dudek K, et al. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113: 884-890
24. Lindor KD, Therneau TM, Jorgensen RA, et al. Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996;110:1515-1518
25. Corpechot C, Carrat F, Bahr A, et al. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005;128:297-303
26. Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol 2002;97:2063-2070
27. Combes B, Luketic VA, Peters MG, et al. Prolonged follow-up of patients in the U.S. Multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. AmJ Gastroenterol 2004;99: 264-268
28. Prince M, Chetwynd A, Newman W, et al. Patient survival and symptom progression in a large geographically based cohort of patients with PBC: Follow up for up to 28 years. Gastroenterology 2002;123:1044-1051
29. Goulis J, Leandor G, Burroughs A. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999;354:1053-1060
30. Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford, United Kingdom: Update Software; 2003
31. Leuschner M, Dietrich CF, You T, et al. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000;46:121-126
32. Van Norstrand MD, Malinchoc M, Lindor K, et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997;25:6-11